Compare Nordic American Tankers Limited Common Stock (NAT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nordic American Tankers Limited Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? Nordic American Tankers Limited Common Stock trades at $8.2 (market cap $1.86B), while Recursion Pharmaceuticals Inc trades at $3.67 (market cap $2.08B). The key difference: Nordic American Tankers Limited Common Stock and Recursion Pharmaceuticals Inc are close in size by market cap, and Nordic American Tankers Limited Common Stock pays a 12.29% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nordic American Tankers Limited Common Stock for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NAT | RXRX | |
|---|---|---|
Market Cap | $1.86B | $2.08B |
Volume | 5,330,493 | 19,700,033 |
Sector | Industrials | Health |
52-Week High | $8.79 | $6.79 |
52-Week Low | $3.26 | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $2.13B | $1.60B |
Dividend Yield | 12.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NAT trades at $8.79, matching its 52-week high, reflecting strong momentum amid favorable tanker market conditions. The stock shows robust fundamentals with a 33.34% net income margin and 25.66% ROE for 2026, while Q2 2026 EPS beat expectations. Technical indicators are neutral, with support and resistance clustered around $9. Recent news highlights surging spot rates and insider buying by the Hansson family, underscoring confidence in near-term prospects.
Outlook is positive due to elevated freight rates and earnings growth, but risks include volatility in tanker rates and geopolitical tensions. Analysts are mixed with a $3.50 consensus target, suggesting caution despite operational strength. The stock's high yield and momentum offer appeal, though sustainability of current rates remains a key monitorable.
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported revenue of $74.26M in 2025 but posted a significant net loss of -$644.76M, reflecting negative profit margins. Recent news highlights strategic AI partnerships and pipeline expansion, though the stock faces high short interest and ongoing operational losses.
Outlook remains speculative with 40% analyst buy ratings but substantial financial losses. Key opportunities include AI-driven drug discovery partnerships, while risks involve cash burn, competitive pressures, and delayed profitability. The stock's valuation at 36.1x sales appears stretched given current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nordic American Tankers Limited Common Stock
Nordic American Tankers Limited is a Bermuda-based shipping company specializing exclusively in Suezmax crude-oil tankers, which it charters in the spot and period markets on international routes. The company has paid a dividend every quarter since 1997.
Read more on NAT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
